The cell and gene therapy market was valued at USD 21.43 Billion in 2025. It is poised to grow at a CAGR of 23.17% during the forecast period of 2026-2035, and reach USD 172.22 Billion by 2035. The market growth is driven by the increasing prevalence of genetic disorders, growing adoption of advanced therapies, and rapid technological advancements in gene editing and delivery systems, driving market growth.
Other key players in the market are Castle Creek Pharmaceutical Holdings, Bristol-Myers Squibb, Kite Pharma, Inc., Vericel Corporation Inc., Kolon TissueGene Inc., Vertex Pharmaceuticals, Inc., Spark Therapeutics, Inc., CORESTEM Inc., Biogen Inc., Dendreon Pharmaceuticals LLC., and JCR Pharmaceuticals Co. Ltd., among others.
Key Market Trends and Insights
- Based on region, North America dominated the market with a revenue share of more than 47% during the historical period.
- By therapy type, the cell therapy manufacturing segment dominated the market with a revenue share of above 59% during the historical period.
- The viral vector segment led by vector type, accounting for approximately 65% share during the historical period, driven by high transfection efficiency and widespread use in approved gene therapies.
Market Size & Forecast
- Market Size in 2025: USD 21.43 Billion
- Projected Market Size in 2035: USD 172.22 Billion
- CAGR from 2026 to 2035: 23.17%
Cell and Gene Therapy Market Overview
The market is expanding rapidly, driven by breakthroughs in genetic engineering and rising demand for targeted treatments. Increasing approvals of advanced therapies, including CAR-T therapy, strong clinical pipelines, and growing investments are supporting growth. Advancements in manufacturing and delivery technologies, along with favorable regulatory support, are further accelerating commercialization and global adoption of innovative therapeutic solutions. The market reached a value of approximately USD 21.43 Billion in 2025.Cell and Gene Therapy Market Growth Drivers
Increasing Regulatory Approvals for Advanced Therapies Driving the Market Value
Rising prevalence of rare diseases and growing regulatory support are key market drivers. For instance, in March 2026, the U.S. FDA approved the first gene therapy for leukocyte adhesion deficiency-I, restoring immune function. This milestone highlights the growing adoption of advanced therapy medicinal product (ATMP) solutions, accelerating commercialization, strengthening clinical confidence, and driving long-term growth in the market.Cell and Gene Therapy Market Trends
Key trends shaping the market include AI integration, gene editing advances, strategic collaborations, and expanding clinical pipelines globally.Integration of AI in Therapy Development Shaping Market Landscape
Advancements in digital technologies and increasing R&D investments are shaping market trends. For instance, in October 2025, AstraZeneca partnered with Algen Biotechnologies in a USD 555 million deal to develop gene therapies using AI platforms. This collaboration is expected to enhance CRISPR-Cas9 innovation, optimize discovery timelines, and improve precision, supporting future market expansion.Cell and Gene Therapy Market Segmentation
Market Breakup by Therapy Type
- Cell Therapy Types
- Autologous Cell Therapy
- Allogenic Cell Therapy
- Gene Therapy Types
- Somatic Gene Therapy
- Germline Gene Therapy
Market Breakup by Type
- Cell Type
- Stem Cell
- Non-Stem Cell
- Gene Type
- Antigen
- Cytokine
- Tumor Suppressor
- Growth Factors
- Receptors
- Others
Market Breakup by Delivery Mode
- In Vivo
- Ex Vivo
Market Breakup by Vector Type
- Viral Vector
- Non-viral Techniques
Market Breakup by Therapeutic Area
- Oncology
- Cardiology Diseases
- Neurological Disorders
- Genetic Disorders
- Infectious Diseases
- Hematological Disorders
- Musculoskeletal Disorders
- Others
Market Breakup by End User
- Hospitals
- Cancer Care Centers
- Academic and Research Institutes
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Cell and Gene Therapy Market Share
Cell Therapy Manufacturing Expected to Dominate Market Segment by Therapy Type
By therapy type, the cell therapy manufacturing segment dominated the market with a revenue share of above 59% during the historical period, driven by increasing clinical adoption and commercialization of personalized treatments. The growing success of CAR-T therapy in oncology has significantly contributed to segment growth. Additionally, expanding clinical pipelines and investments in production capabilities continue to reinforce its leading position globally.Cell and Gene Therapy Market Analysis by Region
North America dominated the market with a revenue share of more than 47% during the historical period, supported by advanced healthcare infrastructure and strong regulatory frameworks. The region benefits from significant investments in biotechnology innovation, particularly in CRISPR-Cas9 technologies. Furthermore, the presence of major industry players and robust clinical trial activity continues to drive regional market expansion.Leading Players in the Cell and Gene Therapy Market
The key features of the market report comprise patent analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:Amgen Inc.Amgen Inc.
California-based Amgen Inc., founded in 1980 and headquartered in Thousand Oaks, is a leading biopharmaceutical company focused on innovative therapeutics for serious diseases. The company invests significantly in next-generation platforms, including CRISPR-Cas9, to advance cell and gene therapy pipelines. Its portfolio spans oncology, cardiovascular, and rare diseases, supported by strong R&D capabilities and global commercialization strategies.Novartis AG
Novartis AG, established in 1996 and headquartered in Basel, Switzerland, is a global pharmaceutical leader with a strong presence in advanced therapies. Its flagship product KYMRIAH, a pioneering CAR-T therapy, is approved for treating B-cell precursor acute lymphoblastic leukemia. The company continues expanding its portfolio across oncology, immunology, and gene therapies through innovation and strategic investments.Pfizer Inc.
Pfizer Inc., founded in 1849 and headquartered in New York, United States, is a multinational biopharmaceutical company actively advancing gene therapy research. The company leverages partnerships and internal innovation to develop treatments using AAV delivery systems. Its portfolio includes therapies targeting rare genetic disorders, oncology, and vaccines, supported by extensive global manufacturing and distribution capabilities.Bluebird Bio, Inc.
Bluebird Bio, Inc., established in 1992 and headquartered in Cambridge, Massachusetts, is a biotechnology company specializing in gene therapies for severe genetic diseases. The company focuses on developing treatments using lentiviral vector technologies. Its portfolio targets conditions such as sickle cell disease and beta-thalassemia, supported by expertise in clinical development and commercialization of transformative therapies.Other key players in the market are Castle Creek Pharmaceutical Holdings, Bristol-Myers Squibb, Kite Pharma, Inc., Vericel Corporation Inc., Kolon TissueGene Inc., Vertex Pharmaceuticals, Inc., Spark Therapeutics, Inc., CORESTEM Inc., Biogen Inc., Dendreon Pharmaceuticals LLC., and JCR Pharmaceuticals Co. Ltd., among others.
Key Questions Answered in the Cell and Gene Therapy Market Report
- What was the cell and gene therapy market value in 2025?
- What is the cell and gene therapy market forecast outlook for 2026-2035?
- What major factors aid the demand for the cell and gene therapy market?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market’s major drivers, opportunities, and restraints?
- What are the major cell and gene therapy market trends?
- Which therapy type is expected to dominate the market segment?
- Which type is expected to dominate the market segment?
- Which delivery mode is expected to dominate the market segment?
- Which vector type is expected to dominate the market segment?
- Which therapeutic area is expected to dominate the market segment?
- Which end user is expected to dominate the market segment?
- Who are the key players in the cell and gene therapy market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
1 Preface
3 Global Cell and Gene Therapy Market Overview
4 Vendor Positioning Analysis
5 Global Cell and Gene Therapy Market Landscape*
6 Global Cell and Gene Therapy Market Dynamics
7 Global Cell and Gene Therapy Market Segmentation (219-2035)
8 North America Global Cell and Gene Therapy Market (219-2035)
9 Europe Global Cell and Gene Therapy Market (219-2035)
10 Asia Pacific Global Cell and Gene Therapy Market (219-2035)
11 Latin America Global Cell and Gene Therapy Market (219-2035)
12 Middle East and Africa Global Cell and Gene Therapy Market (219-2035)
13 Regulatory Framework
14 Clinical Trial Analysis
15 Grant Analysis
16 Funding and Investment Analysis
17 Strategic Initiatives
18 Supplier Landscape
19 Global Cell and Gene Therapy Market - Distribution Model (Additional Insight)
21 Payment Methods (Additional Insight)
Companies Mentioned
- Amgen Inc.Amgen Inc.
- Novartis AG
- Pfizer Inc.
- Bluebird Bio, Inc.
